Production & Sales

Sun Pharma launches ready-to-infuse INFUGEM in the US

Sun Pharmaceutical Industries Ltd. announced that INFUGEM (gemcitabine in sodium chloride injection), for intravenous use, is now commercially available in the U.S.

Merck invests in expansion of manufacturing capacity for biotech medicines

Merck, a leading science and technology company, has announced an investment of €150m in its manufacturing site at Aubonne, Switzerland, to expand manufacturing capacity for its biotech medicines.

bluebird bio opens gene and cell therapy manufacturing facility in North Carolina

bluebird bio announced the official opening of its first wholly owned manufacturing facility in Durham, N.C., that will produce lentiviral vector for the company’s investigational gene and cell therapies, including: bb2121 and bb21217 for the treatment of multiple myeloma and potentially LentiGlobin for the treatment of transfusion-dependent β-thalassemia (TDT) and sickle cell disease.

Mundipharma launches Invokana and Vokanamet in Norway to treat type 2 diabetes

The Mundipharma network of independent associated companies has launched the type-2 diabetes mellitus (T2DM) treatments Invokana (canagliflozin) and Vokanamet (canagliflozin, metformin) in Norway.

Blackstone to buy Japanese specialty pharmaceutical firm Ayumi

Blackstone-managed private equity funds have agreed to acquire Japanese specialty pharmaceutical firm Ayumi Pharmaceutical from an independent private equity firm Unison Capital.

Fujifilm to buy Biogen’s Danish biologics manufacturing site for $890m

Fujifilm has agreed to acquire to acquire Biogen (Denmark) Manufacturing ApS, a large-scale biologics manufacturing site located in Hillerød near Copenhagen, Denmark (Biogen Hillerød), for about $890m in cash.

Ligand sells Promacta assets and Royalty for $827m

Ligand Pharmaceuticals and Royalty Pharma announce the sale of Ligand’s Promacta-related intellectual property rights licensed to Novartis, including the royalty stream on worldwide net sales of Promacta to Royalty Pharma for $827m in cash.

Sagent Pharmaceuticals announces acquisition of Raleigh manufacturing site

Nichi-Iko Pharmaceutical and Sagent Pharmaceuticals, a Nichi-Iko Group Company ("Sagent"), a leader of specialty pharmaceutical products with an emphasis on the injectable market, announced that Sagent has acquired an FDA-approved manufacturing site in Raleigh, North Carolina, from Xellia Pharmaceuticals ("Xellia").

Bausch Health to buy certain assets of Synergy Pharmaceuticals

Bausch Health announced that the company was selected as the successful bidder to acquire certain assets of Synergy Pharmaceuticals for a cash purchase price of approximately $195m and the assumption of certain assumed liabilities, pursuant to the terms of the stalking horse asset purchase agreement previously entered into with the company.